← Leaderboards
Balaji Narasimhan
Iowa State University
$10,147,669
Attributed
$13,675,448
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,675,448 · 5
By mechanism
R01$10,485,283 · 3
U01$2,652,788 · 1
R56$537,377 · 1
Top collaborators
- Maneesh Jain5 shared
- Marian L Kohut5 shared
- Aliasger K Salem5 shared
Most similar at Iowa State University
Same institution · by research overlap
- Marian L Kohut$5,498,591
- Jodi McGill$1,268,187
- Randy E Sacco$1,038,687
- Maria P Torres-Gonzalez$53,588
- Michael J Wannemuehler$142,961
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseNanoparticleDesignVaccinesPolyanhydridesLeadAntigensImmunizationFormulationNanovaccineT Cell ResponseBaseAdjuvantImmuneRecombinantsRespiratoryDoseTechnologyInnovationCellular ImmunityB-LymphocytesImmune ResponseImmunityInfection
Grant awards (20)
Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection$632,725
R01 · FY2025 · AI
Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection$716,728
R01 · FY2024 · AI
Universal room temperature stable influenza nanovaccine$965,238
R01 · FY2023 · AI · contact PI
Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection$716,177
R01 · FY2023 · AI
Universal room temperature stable influenza nanovaccine$1,090,313
R01 · FY2022 · AI · contact PI
Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection$723,073
R01 · FY2022 · AI
Universal room temperature stable influenza nanovaccine$1,047,614
R01 · FY2021 · AI · contact PI
Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection$729,805
R01 · FY2021 · AI
Nanovaccine platforms to combat pancreatic cancer$507,337
U01 · FY2021 · CA · contact PI
Universal room temperature stable influenza nanovaccine$1,132,987
R01 · FY2020 · AI · contact PI
Nanovaccine platforms to combat pancreatic cancer$506,063
U01 · FY2020 · CA · contact PI
Universal room temperature stable influenza nanovaccine$1,339,376
R01 · FY2019 · AI · contact PI
Nanovaccine platforms to combat pancreatic cancer$529,150
U01 · FY2019 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$543,977
U01 · FY2018 · CA · contact PI
Nanovaccine platforms to combat pancreatic cancer$566,261
U01 · FY2017 · CA · contact PI
Enhanced Shelf-life Nanovaccine Formulation for Immunity to Biodefense Pathogens$345,724
R01 · FY2017 · AI · contact PI
Enhanced Shelf-life Nanovaccine Formulation for Immunity to Biodefense Pathogens$346,838
R01 · FY2016 · AI · contact PI
Enhanced Shelf-life Nanovaccine Formulation for Immunity to Biodefense Pathogens$348,686
R01 · FY2015 · AI · contact PI
Enhanced Shelf-life Nanovaccine Formulation for Immunity to Biodefense Pathogens$349,999
R01 · FY2014 · AI · contact PI
Impact of polymer adjuvant chemistry on adaptive immune mechanisms$537,377
R56 · FY2010 · AI · contact PI